Drug intelligence / Profile preview

Tenvir

Development stage
Unknown
Lead developer
Gilead Sciences
Modality
Small Molecules
Administration
Oral
01

Overview

Tenvir is an antiviral medication containing tenofovir disoproxil fumarate (TDF), a nucleotide reverse transcriptase inhibitor (NRTI). It is primarily used for the treatment of HIV-1 infection and chronic hepatitis B virus (HBV) infection. As a prodrug, it is converted intracellularly to tenofovir diphosphate, which acts as an analog of deoxyadenosine 5'-triphosphate. It competes with the natural substrate for incorporation into viral DNA via the HIV-1 reverse transcriptase or HBV polymerase enzymes. Once incorporated, it causes viral DNA chain termination because it lacks the 3'-hydroxyl group necessary for further phosphodiester bond formation. Tenvir is distributed by Magicine Pharma and is part of the ARECHAR product portfolio, serving as a critical component of antiretroviral therapy (ART) to reduce viral load and improve immune function.

Brand names
Tenvir
Other names
Tenofovir disoproxil fumarate 300 mgTDF
02

Targets

Human immunodeficiency virus type 1 reverse transcriptaseHBV Pol (Hepatitis B virus polymerase)

Beyond the preview

Go deeper on Tenvir.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tenvir.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call